Tirzepatide represents a groundbreaking pharmaceutical agent for individuals facing type 2 diabetes. As a dual agonist, it targets both the glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic https://victorjuui297299.bloggactif.com/41996708/tirzepatide-a-novel-glp-1-and-gip-receptor-agonist